- Home
- VGI vs ONCY Comparison
VGI vs ONCY Comparison
Compare VGI & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- ONCY
- Stock Information
- Founded
- VGI 2012
- ONCY 1998
- Country
- VGI United States
- ONCY Canada
- Employees
- VGI N/A
- ONCY N/A
- Industry
- VGI Investment Managers
- ONCY Pharmaceuticals and Biotechnology
- Sector
- VGI Finance
- ONCY Health Care
- Exchange
- VGI Nasdaq
- ONCY Nasdaq
- Market Cap
- VGI 89.7M
- ONCY 89.7M
- IPO Year
- VGI N/A
- ONCY 1999
- Fundamental
- Price
- VGI $8.02
- ONCY $1.28
- Analyst Decision
- VGI
- ONCY Strong Buy
- Analyst Count
- VGI 0
- ONCY 5
- Target Price
- VGI N/A
- ONCY $5.00
- AVG Volume (30 Days)
- VGI 46.0K
- ONCY 1.2M
- Earning Date
- VGI 01-01-0001
- ONCY 11-11-2025
- Dividend Yield
- VGI 12.66%
- ONCY N/A
- EPS Growth
- VGI N/A
- ONCY N/A
- EPS
- VGI N/A
- ONCY N/A
- Revenue
- VGI N/A
- ONCY N/A
- Revenue This Year
- VGI N/A
- ONCY N/A
- Revenue Next Year
- VGI N/A
- ONCY N/A
- P/E Ratio
- VGI N/A
- ONCY N/A
- Revenue Growth
- VGI N/A
- ONCY N/A
- 52 Week Low
- VGI $6.68
- ONCY $0.33
- 52 Week High
- VGI $7.99
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- VGI 57.06
- ONCY 61.30
- Support Level
- VGI $8.02
- ONCY $1.05
- Resistance Level
- VGI $8.09
- ONCY $1.44
- Average True Range (ATR)
- VGI 0.05
- ONCY 0.11
- MACD
- VGI 0.00
- ONCY 0.02
- Stochastic Oscillator
- VGI 53.20
- ONCY 67.35
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.